Update on lipoprotein(a) as a cardiovascular risk factor and mediator. (Q38132701)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23990263%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Update on lipoprotein(a) as a cardiovascular risk factor and mediator (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23990263%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

0 references

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23990263%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Marlys L Koschinsky

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23990263%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

1 reference

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23990263%20AND%20SRC:MED&resulttype=core&format=json

Current Atherosclerosis Reports

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23990263%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23990263%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23990263%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

360

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23990263%20AND%20SRC:MED&resulttype=core&format=json

Lipoprotein(a): more interesting than ever after 50 years

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lipoprotein(a): resurrected by genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Emerging therapeutic agents to lower lipoprotein (a) levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

cDNA sequence of human apolipoprotein(a) is homologous to plasminogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Novel insights into Lp(a) physiology and pathogenicity: more questions than answers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Molecular definition of the extreme size polymorphism in apolipoprotein(a).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Farnesoid X receptor represses hepatic human APOA gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

FGF19 signaling cascade suppresses APOA gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Evidence of dependence of lipoprotein(a) on triglyceride and high-density lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Niacin and cholesterol: role in cardiovascular disease (review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Mechanism of action of niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lipoprotein(a) as a cardiovascular risk factor: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Prevalence of risk factors in men with premature coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Antisense oligonucleotides for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Genetic variants associated with Lp(a) lipoprotein level and coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein(A) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lack of association between four SNPs in the SLC22A3-LPAL2-LPA gene cluster and coronary artery disease in a Chinese Han population: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

What is the role of advanced lipoprotein analysis in practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Euglobulin clot lysis induced by tissue-type plasminogen activator is reduced in subjects with increased levels of lipoprotein (a).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Predictors of aortic and coronary artery calcium on a screening electron beam tomographic scan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lack of association between lipoprotein(a) and coronary artery calcification in the Genetic Epidemiology Network of Arteriopathy (GENOA) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Association of lipoprotein subfractions and coronary artery calcium in patient at intermediate cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Lipoprotein (a) is independently correlated with coronary artery calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

Genetic associations with valvular calcification and aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-013-0360-6

21 January 2018

1 reference

12 December 2020

Heterogeneity of human plasma lipoprotein (a). Isolation and characterization of the lipoprotein subspecies and their apoproteins

1 reference

12 December 2020

The prevalence and severity of coronary artery calcification on coronary artery computed tomography in black and white subjects

1 reference

12 December 2020

Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans

1 reference

12 December 2020

Genetic variants in the apolipoprotein(a) gene and coronary heart disease

1 reference

12 December 2020

Associations between serum lipoprotein(a) levels and the severity of coronary and aortic atherosclerosis

1 reference

12 December 2020

Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100.

1 reference

12 December 2020

Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature

1 reference

12 December 2020

Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis

1 reference

12 December 2020

In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a)

1 reference

12 December 2020

Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes

1 reference

12 December 2020

Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study

1 reference

12 December 2020

Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment

1 reference

12 December 2020